Skip to main content

Table 1 Patient characteristics of the present study population

From: CA-125–indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery

Characteristic No. of patients (%)
Median age, years (range) 58.6 (23.5–89.2)
Median CA-125 level at diagnosis, U/ml (range) 490.5 (7–33439)
Median nadir CA-125 level, U/ml (range) 10 (4–35)
Ethnicity  
 White 316 (77.1)
 Black 25 (6.1)
 Hispanic 56 (13.7)
 Other* 13 (3.2)
Histology  
 Serous 317 (77.3)
 Endometrioid 42 (10.2)
 Clear cell 18 (4.4)
 Mucinous 9 (2.2)
 Transitional 6 (1.5)
 Undifferentiated 9 (2.2)
 MMMT 9 (2.2)
Grade  
 High 361 (88.0)
 Low 49 (12.0)
FIGO stage  
 I 42 (10.2)
 II 31 (7.6)
 III 284 (69.3)
 IV 53 (12.9)
Residual disease after primary surgery  
 Optimal ( 1 cm) 322
 Suboptimal (> 1 cm) 65
 Unknown 23
NACT  
 Yes 46 (11.2)
 No 354 (86.3)
 Unknown 10 (2.4)
  1. Note: All data are no. of patients (%) unless noted otherwise.
  2. Abbreviations: MMMT, malignant mixed müllerian tumor; FIGO, International Federation of Gynecology and Obstetrics; NACT, Neoadjuvant chemotherapy.
  3. *5 Chinese, 4 Middle Eastern, 1 Japanese, 1 Korean, and 2 Indian patients.